Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15414896 | 0.88 | KDM4E (0.46) | KDM4ETDP1MAOAMAOBALDH1A1 | |
| SCHEMBL12277345 | 0.81 | KMT2A (0.46) | KDM4ETDP1MAOAMAOBALDH1A1 | |
| SCHEMBL27943843 | 0.77 | TDP1 (0.52) | KDM4ETDP1MAOAMAOBALDH1A1 | |
| SCHEMBL3970688 | 0.77 | PDE10A (0.56) | KDM4EALDH1A1GAAHPGDHTT | |
| SCHEMBL5469806 | 0.76 | MAOA (0.56) | KDM4ETDP1MAOAMAOBALDH1A1 | |
| Methane SCHEMBL27539281 | 0.75 | ERN1 (0.47) | KDM4ETDP1MAOAMAOBALDH1A1 | |
| SCHEMBL9611245 | 0.73 | KDM4E (0.57) | KDM4ETDP1MAOAMAOBALDH1A1 | |
| SCHEMBL30631523 | 0.73 | MAOA (0.47) | KDM4ETDP1MAOAMAOBALDH1A1 | |
| SCHEMBL26615790 | 0.73 | MAOA (0.47) | KDM4ETDP1MAOAMAOBALDH1A1 | |
| SCHEMBL15978466 | 0.73 | ALDH1A1 (0.52) | KDM4ETDP1MAOAMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135478-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-11-14 | — | — | US | disclosed |
| US-7053102-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-05-30 | — | — | US | disclosed |
| EP-1251125-B1 | New camptothecin analogues, preparation methods thereof, use thereof as drugs, and pharmaceutical compositions containing them | SOD CONSEILS RECH APPLIC (FR) | 2005-12-07 | — | — | EP | disclosed |
| CN-1227254-C | Pyridone compound and its prepn process | SOD CONSEILS RECH APPLIC (FR) | 2005-11-16 | — | — | CN | disclosed |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2005-02-17 | — | — | US | disclosed |
| US-20040254163-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2004-12-16 | — | — | US | disclosed |
| US-6815546-B2 | ANTICANCER AGENTS | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-11-09 | — | — | US | disclosed |
| US-6797715-B1 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-09-28 | — | — | US | disclosed |
| US-6762301-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-13 | — | — | US | disclosed |
| EP-0946566-B1 | PRO-DRUGS AND COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINES | SOD CONSEILS RECH APPLIC (FR) | 2003-11-05 | — | — | EP | disclosed |
| CN-1241192-A | Pro-drugs and counterparts of camptothecin, their application as medicines | SOD CONSEILS RECH APPLIC (FR) | 2000-01-12 | — | — | CN | disclosed |
| US-5981542-A | TOPOISOMERASE INHIBITORS; ANTITUMORAL DRUGS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-11-09 | — | — | US | disclosed |
| EP-0946567-A1 | NOVEL COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-10-06 | — | — | EP | disclosed |
| EP-0946566-A1 | PRO-DRUGS AND COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999033829-A1 | NOVEL CAMPTOTHECIN TETRACYCLIC ANALOGUES, PREPARATION, METHODS, APPLICATIONS AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-07-08 | — | — | WO | disclosed |
| CN-1192740-A | Novel camptothecin analogues, their preparation method, their pharmaceutical use and their pharmaceutical compositions | SOD CONSEILS RECH APPLIC (FR) | 1998-09-09 | — | — | CN | disclosed |
| WO-1998028304-A1 | PRO-DRUGS AND COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998028305-A1 | NOVEL COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1998-07-02 | — | — | WO | disclosed |
| EP-0835258-A1 | NOVEL CAMPTOTHECIN ANALOGUES, PREPARATION METHODS THEREFOR, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID ANALOGUES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997000876-A1 | NOVEL CAMPTOTHECIN ANALOGUES, PREPARATION METHODS THEREFOR, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID ANALOGUES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254163-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP2A, TOP1, MCL1 | KDM4E 4381/4885TDP1 1158/4885RXFP1 4661/4885 |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | MCL1, BRCA1, API5 | KDM4E 699/4885TDP1 1245/4885RXFP1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.